Procept Biorobotics Net Income Over Time
| PRCT Stock | USD 28.96 0.16 0.55% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Procept Biorobotics Performance and Procept Biorobotics Correlation. Is there potential for Health Care Equipment & Supplies market expansion? Will Procept introduce new products? Factors like these will boost the valuation of Procept Biorobotics. Anticipated expansion of Procept directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Procept Biorobotics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.53) | Revenue Per Share | Quarterly Revenue Growth 0.428 | Return On Assets | Return On Equity |
Understanding Procept Biorobotics Corp requires distinguishing between market price and book value, where the latter reflects Procept's accounting equity. The concept of intrinsic value—what Procept Biorobotics' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Procept Biorobotics' price substantially above or below its fundamental value.
It's important to distinguish between Procept Biorobotics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Procept Biorobotics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Procept Biorobotics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare Procept Biorobotics Corp and related stocks such as Twist Bioscience Corp, Guardian Pharmacy, and Mesoblast Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TWST | (44.1 M) | (44.1 M) | (44.1 M) | (44.1 M) | (44.1 M) | (44.1 M) | (59.3 M) | (71.2 M) | (107.7 M) | (139.9 M) | (152.1 M) | (217.9 M) | (204.6 M) | (208.7 M) | (77.7 M) | (69.9 M) | (73.4 M) |
| GRDN | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 21.7 M | 19.9 M | 16.3 M | 35.4 M | 23.9 M | (87.3 M) | (78.6 M) | (74.6 M) |
| MESO | (1.5 M) | (71.1 M) | (61.7 M) | (81 M) | (119.4 M) | (4.1 M) | (76.8 M) | (35.3 M) | (89.8 M) | (77.9 M) | (98.8 M) | (91.3 M) | (81.9 M) | (88 M) | (102.1 M) | (91.9 M) | (87.3 M) |
| BGM | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 5.2 M | 5.3 M | 5.1 M | 3.2 M | 1.1 M | (7.8 M) | (1.4 M) | (1.4 M) | (1.3 M) | (1.2 M) |
| QDEL | (100 K) | 7.6 M | 5 M | 7.4 M | (7.1 M) | (6.1 M) | (13.8 M) | (8.2 M) | 74.2 M | 72.9 M | 810.3 M | 704.2 M | 548.7 M | (10.1 M) | (2.1 B) | (1.8 B) | (1.8 B) |
| EWTX | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (17.1 M) | (42.1 M) | (15.4 M) | (100.2 M) | (133.8 M) | (120.4 M) | (114.4 M) |
| CLOV | (201.9 M) | (201.9 M) | (201.9 M) | (201.9 M) | (201.9 M) | (201.9 M) | (201.9 M) | (201.9 M) | (201.9 M) | (363.7 M) | (136.4 M) | (587.8 M) | (339.6 M) | (213.4 M) | (43 M) | (49.5 M) | (51.9 M) |
| AORT | (700 K) | 7.4 M | 7.9 M | 16.2 M | 7.3 M | 4 M | 10.8 M | 3.7 M | (3.8 M) | 1.7 M | (16.7 M) | (14.8 M) | (19.2 M) | (30.7 M) | (13.4 M) | (12 M) | (11.4 M) |
| INSP | (21.3 M) | (21.3 M) | (21.3 M) | (21.3 M) | (21.3 M) | (21.3 M) | (18.5 M) | (17.5 M) | (21.8 M) | (33.2 M) | (57.2 M) | (42 M) | (44.9 M) | (21.2 M) | 53.5 M | 61.5 M | 64.6 M |
| SSII | (66.0) | (66.0) | (66.0) | (66.0) | (66.0) | (66.0) | (485 K) | (1 M) | (960.3 K) | (3.4 M) | (1.1 M) | (1.5 M) | (5.6 M) | (20.9 M) | (19.2 M) | (17.2 M) | (16.4 M) |
Procept Biorobotics Corp and related stocks such as Twist Bioscience Corp, Guardian Pharmacy, and Mesoblast Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Procept Biorobotics Corp financial statement analysis. It represents the amount of money remaining after all of Procept Biorobotics Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Procept Biorobotics Corp | PRCT |
Specialization | Health Care, Health Care Equipment & Services |
| Business Address | 150 Baytech Drive, |
| Exchange | NASDAQ Exchange |
USD 28.96
Additional Tools for Procept Stock Analysis
When running Procept Biorobotics' price analysis, check to measure Procept Biorobotics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Procept Biorobotics is operating at the current time. Most of Procept Biorobotics' value examination focuses on studying past and present price action to predict the probability of Procept Biorobotics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Procept Biorobotics' price. Additionally, you may evaluate how the addition of Procept Biorobotics to your portfolios can decrease your overall portfolio volatility.